Phase 2a scientific trial describes security and efficacy of dendrimer nanotherapy in extreme COVID-19 sufferers
  • Reading time:5 min(s) read

A multicenter, randomized, placebo-controlled part 2a scientific trial has lately been performed to guage the efficacy of a nanotherapeutic compound OP-101 in treating extreme coronavirus illness 2019 (COVID-19) sufferers. An in depth report of the scientific trial has been revealed within the journal Science Translational Medicine.

Study: Dendrimer nanotherapy for extreme COVID-19 attenuates irritation and neurological damage markers and improves outcomes in a phase2a scientific trial. Image Credit: CROCOTHERY/Shutterstock


Hyperinflammation is a significant hallmark of extreme COVID-19, a novel illness attributable to extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Activated tissue macrophages and monocytes play essential roles in hyperinflammation in addition to the pathogenesis of acute respiratory misery syndrome (ARDS).

Besides respiratory misery, extreme COVID-19 is related to neurological signs, together with delirium, agitation, encephalopathy, and stroke. A rising pool of proof means that neurological penalties are related to systemic irritation that triggers neuroinflammation and mind dysfunction.

In this part 2a scientific trial, scientists have investigated the protection and efficacy of OP-101 in ameliorating irritation and mind damage in extreme COVID-19 sufferers.  

OP-101 is a hydroxyl-polyamidoamine dendrimer–N-acetylcysteine conjugate that has beforehand been examined in animal fashions of systemic and neuroinflammation. The compound exerts potent anti-inflammatory and antioxidant capabilities by releasing N-acetylcysteine in activated macrophages and microglia.

Trial design

A complete of 24 sufferers with extreme COVID-19 had been randomized into 4 teams, together with a placebo group and three therapy teams. In the therapy teams, the sufferers obtained a single intravenous dose of two mg/kg (n=6), 4 mg/kg (n=6), or 8 mg/kg (n=5) of OP-101. In the placebo group, seven sufferers obtained a single intravenous dose of a placebo drug.

In addition to OP-101 or placebo, all contributors obtained corticosteroids as the usual of care therapy.

Therapeutic efficacy of OP-101

C-reactive protein (CRP) is a well-established marker of systemic irritation. An elevated stage of serum CRP has generally been seen in extreme COVID-19 sufferers.

In the trial, a gentle and sustained discount in serum CRP stage was noticed in sufferers handled with OP-101. Specifically, OP-101-treated sufferers exhibited a higher than 20% discount in CRP stage per day in comparison with a decrease than 5% discount in placebo-treated sufferers. The highest impact was noticed at 4 mg/kg of OP-101 dose.

Neurological damage markers

Three markers of neurological damage, together with neurofilament mild chain (NFL), Tau protein, and glial fibrillary acidic protein (GFAP), had been measured within the trial. Previous research have proven that extreme COVID-19 sufferers exhibit excessive serum ranges of neurological damage markers, regardless of utilizing corticosteroids as the usual of care.

In the trial, two greater doses of OP-101 (4 mg/kg and eight mg/kg) confirmed vital efficacy in decreasing the serum ranges of NFL and GFAP in comparison with the placebo therapy. However, no vital therapy impact of OP-101 was noticed for Tau protein.

Pro-inflammatory markers

Several inflammatory markers together with tumor necrosis issue–α (TNF-α), interleukin (IL)-6, IL-8, IL-22, and IL-10 had been measured within the trial.

The OP-101 therapy at a dose of 4 mg/kg confirmed considerably greater efficacy than the placebo therapy in decreasing serum ranges of TNF-α, IL-6, and IL-8. However, no vital therapy impact of OP-101 was noticed for IL-10 and IL-22.

Clinical outcomes

A big enchancment in survival charge was noticed amongst sufferers handled with OP-101. While 43% survival was noticed within the placebo group, the therapy with 2 mg/kg, 4 mg/kg, and eight mg/kg of OP-101 resulted in 67%, 100%, and 80% survival, respectively. Notably, not one of the surviving sufferers within the OP-101 therapy teams required mechanical air flow through the examine interval (60 days).

Overall, the danger of extreme scientific outcomes (mechanical air flow or loss of life) at day 30 post-infusion was 71% in placebo-treated sufferers and 18% in OP-101-treated sufferers.

Safety profile of OP-101

No vital variations in adversarial occasions had been noticed between the placebo and OP-101 therapy teams. Treatment-emergent adversarial occasions had been noticed in 70% of OP-101-treated sufferers and 71% of placebo-treated sufferers. Treatment-emergent adversarial occasions embrace both new-onset adversities or already-existing adversities that worsen due to the therapy.

Since all sufferers enrolled within the trial had been critically ailing, they’re anticipated to exhibit treatment-emergent adversarial occasions. This explains why no vital variations in adversities had been noticed between the teams.

To additional examine the protection profile of OP-101, two kidney damage markers (kidney damage molecule-1 and neutrophil gelatinase-associated lipocalin) had been thought-about, provided that OP-101 is primarily faraway from the circulation by means of the kidney. However, no vital variations within the urinary ranges of each markers had been noticed between the placebo and OP-101 therapy teams.


The scientific trial highlights the therapeutic efficacy of a nanomedicine OP-101 in critically ailing COVID-19 sufferers. The compound displays excessive efficacy in decreasing inflammatory and neurological damage markers and bettering scientific outcomes.

Journal reference:

  • Gusdon AM. (2022). Dendrimer nanotherapy for extreme COVID-19 attenuates irritation and neurological damage markers and improves outcomes in a phase2a scientific trial. Science Translational Medicine. doi: 10.1126/scitranslmed.abo2652

If you are interested in working in a distraction free environment, visit our site Blissful Noises where we provide various sounds and features to help you focus or relax.